Investigating the effect of Tranexamic acid drug in cardiopulmonary bypass device

Investigating the effect of Tranexamic acid acid drug in the prime solution of the cardiopulmonary bypass system on the amount of bleeding after surgery in open heart surgeries.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240220061056N1

Enrollment

Registered

2024-05-14

Start date

2024-03-28

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Investigating the amount of bleeding in heart surgery. Heart failure, unspecified

Interventions

Intervention 1: Intervention group: The use of tranexamic acid drug at a dose of 15 mg/kg as a single dose is injected into the prime solution of the cardiopulmonary bypass device before the start of

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: People with coronary artery problems and heart valve problems who need surgery and undergo cardiopulmonary bypass pump surgery.

Exclusion criteria

Exclusion criteria: under of 18 years History of seizures before surgery History of embolism before surgery

Design outcomes

Primary

Measure	Time frame
Bleeding rate after surgery. Timepoint: 24 hours after the operation. Method of measurement: chest bottle blood volume.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Seyed Hossein Moshtaghion

Yazd University of Medical Sciences

javad.mc.111@gmail.com+98 35 3525 5011

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026